Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia
Stock Information for Minerva Neurosciences Inc
Loading
Please wait while we load your information from QuoteMedia.